Tempus

Deep 6 AI Inc. is a technology company that specializes in patient trial matching for clinical research through its artificial intelligence-based platform. Founded in 2013 and based in Pasadena, California, the company leverages advanced AI and natural language processing to analyze both structured data, such as ICD-10 codes, and unstructured clinical information, including doctor’s notes and pathology reports. This innovative approach enables the extraction of critical clinical data points, such as symptoms and treatment histories, transforming fragmented medical records into unified patient graphs. By identifying patients who may meet complex clinical trial criteria, even those with conditions not explicitly documented in their medical records, Deep 6 AI enhances the efficiency of patient recruitment for clinical trials, ultimately aiming to accelerate the development of new treatments. The company was previously known as Deep 6 Analytics, LLC before rebranding in March 2017.

Ambry Genetics is a privately-held healthcare company specializing in genetic testing solutions for inherited and non-inherited diseases. It offers a comprehensive suite of genetic testing applications, including gene testing, classification, and sequencing. The company is committed to scientific collaboration and emphasizes the importance of sharing anonymized patient records with the global medical research community. This approach aims to advance the understanding and management of human diseases while supporting the belief that human health should remain accessible and not be patented or owned. Ambry's services are designed to benefit a significant majority of U.S. patients who are covered by public and private insurers.

Personalis, Inc. is a cancer genomics company based in Menlo Park, California, that specializes in genomic sequencing and data analysis services aimed at advancing personalized cancer therapies. Established in 2011, the company offers a range of products, including the NeXT Platform, which provides critical data for the development of personalized therapies, therapy selection, and diagnostics. Additionally, Personalis provides a liquid biopsy assay that examines various human genes to enhance cancer treatment strategies. The company's services support biopharmaceutical clients, universities, non-profit organizations, diagnostics companies, and government agencies, facilitating the creation of safer and more effective precision cancer therapies and immunotherapies. Personalis is recognized for its integration of sequencing technology and data interpretation, contributing to a comprehensive understanding of tumor biology and its interaction with the immune system.

Dawson Forte Cashmere is a retailer of cashmere products, including gloves, scarves, and accessories. They offer cashmere clothing, portfolio of label knitwear made of silk and woollen materials, allowing for both men's and women's garments.

Mpirik is a healthcare intelligence platform designed to enhance patient care by identifying critical findings and filtering out extraneous data. The platform aggregates health data and standardizes patient communication, enabling clinicians to track patients throughout the progression of their diseases. By ensuring timely follow-ups and facilitating effective communication, Mpirik empowers healthcare professionals to deliver high-quality care. Its technology aims to provide a consistent and objective approach to patient screening, thereby improving the overall efficiency and effectiveness of healthcare delivery.

Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

Arterys Inc. is a pioneering company in the field of medical imaging analytics, focused on transforming healthcare through advanced radiology solutions. Established in 2007 and headquartered in San Francisco, California, with additional offices in Calgary, Canada, and Paris, France, Arterys offers a web-based, AI-powered platform that is FDA-cleared and designed to enhance patient care. Its suite of products includes Cardio AI for cardiac magnetic resonance image analysis, Lung AI for lung imaging, Liver AI for liver imaging, and Chest/MSK AI, which automates the detection of various conditions such as fractures and pulmonary nodules. Additionally, the Arterys PHI Service allows physicians to access patient data remotely. The platform's innovative technology enables radiologists to visualize and quantify blood flow in the human body, facilitating improved diagnostic capabilities and clinical decision-making.

Highline Sciences is a specialized clinical contract research organization (CRO) that concentrates on oncology. The company is dedicated to managing and executing both early and late-stage clinical trials, tailoring its approach to meet the unique requirements of each study. In addition to trial management, Highline Sciences offers a range of services including clinical development consulting, clinical staffing, and marketing and commercial support. This comprehensive service offering enables clients to effectively navigate the complexities of clinical development and achieve their specific objectives in the oncology sector.

Akrivia Health is a developer of an AI-driven software-as-a-service (SaaS) platform that focuses on enhancing clinical research and drug discovery in the healthcare sector. The company specializes in providing real-world data for evidence generation, optimizing clinical trials, and molecular characterization, particularly in areas such as mental health and dementia. Through its innovative approach, Akrivia Health offers a federated data and information governance model that aids in managing patient records and facilitating early-stage drug discovery. Additionally, the platform supports market analysis and clinical trial revenue management, enabling researchers and healthcare professionals to leverage clinical data literature for improved patient care and research outcomes.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia, that serves a diverse clientele, including the pharmaceutical, biotechnology, clinical, academic, and government sectors. Established in 2010, the company specializes in clinical trials, diagnostic testing, and research, with a particular focus on oncology and personalized medicine. AKESOgen offers a wide range of services, including high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (both NGS and Sanger), genotyping, and epigenomic analysis, all conducted to CLIA/GLP standards. Additionally, the company provides clinical and regulatory services, ensuring compliance with clinical trial protocols and molecular pathology. Its notable clients include the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente.

8Trip, a China-based online travel service which connects suppliers with sellers. Currently, 8Trip covers the markets of Wuxi, Nanjing, and Anhui in China, and is planning to enter the Shanghai market next year. The company has partnerships with about 1,000 travel agencies and more than 4,000 service outlets. 8Trip was founded in December 2011 under the company name Octopus Online Tourism Development, with headquarters in Suzhou.

Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to address a range of conditions, including neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is advancing XCUR-FXN, an SNA-based therapeutic for Friedreich’s ataxia in preclinical trials, and XCUR17, which targets the mRNA encoding interleukin 17 receptor alpha. The company has established collaborations with Allergan Pharmaceuticals to develop SNA-based treatments for hair loss and with DERMELIX, LLC for research and commercialization efforts related to netherton syndrome. Founded in 2011, Exicure is developing a new class of immunomodulatory and gene silencing drugs that enhance the delivery and efficacy of nucleic acid therapeutics.

Exicure, Inc. is a clinical-stage biotechnology company based in Chicago, Illinois, focused on developing therapeutics utilizing its proprietary spherical nucleic acid (SNA) technology. The company aims to address a range of conditions, including neurological disorders, immuno-oncology, inflammatory diseases, and genetic disorders. Its lead drug candidate, AST-008, is currently undergoing Phase 1b/2 clinical trials for advanced solid tumors. Additionally, Exicure is advancing XCUR-FXN, an SNA-based therapeutic for Friedreich’s ataxia in preclinical trials, and XCUR17, which targets the mRNA encoding interleukin 17 receptor alpha. The company has established collaborations with Allergan Pharmaceuticals to develop SNA-based treatments for hair loss and with DERMELIX, LLC for research and commercialization efforts related to netherton syndrome. Founded in 2011, Exicure is developing a new class of immunomodulatory and gene silencing drugs that enhance the delivery and efficacy of nucleic acid therapeutics.